Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Mer
A research initiative in multiple sclerosis launched with support from Novartis has partnered with Seqster to provide a unified platform for data sharing, supporting patie
Contineum Therapeutics has become the latest biotech to file for an initial public offering (IPO) in the US, hoping to raise $150 million for its early clinical-stage cand
The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qua
Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th
As we move forward in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh